Macrophage and Microglial Activation in Glioma-Associated Inflammation

胶质瘤相关炎症中的巨噬细胞和小胶质细胞激活

• 批准号: 7582246
• 负责人: NALIN GUPTA
• 金额: $ 16.14万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-19 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7582246
• 关键词: Address; Adult; Anaplastic astrocytoma; Animals; Astrocytes; Attenuated; Binding; Blood Vessels; Bone Marrow; Bone Marrow Transplantation; Brain; Brain Neoplasms; CCL2 gene; California; Cells; Central Nervous System Diseases; Central Nervous System Neoplasms; Child; Childhood; Chronic; Classification; Clinical; Clinical Research; Cytokine Receptors; Data; Demyelinations; Development; Disease; Ectopic Expression; Endothelial Cells; Environment; Family; Flow Cytometry; GTP-Binding Proteins; Genetic; Glioma; Goals; Growth; Hematogenous; Histologic; Human; Hypoxia; Immunity; Immunohistochemistry; Immunology; Immunosuppression; Implant; In Vitro; Inbred Strains Mice; Incidence; Infiltration; Inflammation; Inflammatory; Inflammatory Response; Injury; Integrins; Israel; Knock-out; Knockout Mice; Label; Ligands; Malignant neoplasm of brain; Measures; Mediating; Mentors; Microglia; Monocyte Chemoattractant Protein-1; Multiple Sclerosis; Mus; Necrosis; Neoplasm Metastasis; Neurosurgeon; Nomenclature; Normal tissue morphology; Oncogenes; Pathogenesis; Patients; Pharmaceutical Preparations; Play; Primary Brain Neoplasms; Process; Radiation; Recruitment Activity; Research; Research Personnel; Research Project Grants; Resistance; Role; San Francisco; Secondary to; Signal Pathway; Specimen; Stimulus; Subgroup; System; Systemic Therapy; Target Populations; Testing; Therapeutic Agents; Tissues; Training; Transgenic Mice; Tumor Biology; Tumor Necrosis Factor-alpha; Tumor-Derived; Universities; Virus Diseases; angiogenesis; antitumor agent; beta-Chemokines; career; chemokine; chemokine receptor; clinically relevant; cytokine; experience; implantation; inhibitor/antagonist; interest; local drug delivery; loss of function; macrophage; migration; monocyte; monocyte chemoattractant protein 1 receptor; mouse model; neoplastic cell; neuro-oncology; oligodendroglioma; overexpression; programs; public health relevance; receptor; response; small molecule; tissue processing; tumor; tumor growth; v-erbB Oncogenes

The goal of this project is to provide the applicant, Nalin Gupta, with the necessary expertise to develop an independent research career at the University of California San Francisco by building on his previous experience and training. This will be accomplished through a mentored research project supervised by Dr. Israel F. Charo, and additional training in immunology and use of transgenic mouse models. Dr. Gupta is a pediatric neurosurgeon with a clinical and research interest in neuro-oncology. His project, 'Macrophage and microglial activation in glioma-associated inflammation1 addresses an understudied aspect of brain tumor biology: the interactions between inflammatory cells and tumor cells. The hypothesis of this project is that macrophages and microglia are recruited to high-grade gliomas by overexpression of a specific chemokine, monocyte chemoattractant protein-1 (MCP-1), and that this process facilitates tumor growth. The specific aims that will test this hypothesis are: a) determine the origin of tumor-associated macrophages, b) measure the effect of loss of the CCR2 cytokine receptor on glioma growth in mice developing oligodendrogliomas, and c) determine the contribution of tumor and host-derived MCP-1 on glioma growth. The importance of MCP-1 is suggested by its ubiquity in high-grade gliomas, its correlation with infiltrating macrophages, and data supporting a role for this cytokine in angiogenesis and tumor cell migration. The effect of macrophages and microglia on glioma growth will be directly examined using a genetic approach in transgenic mice. Mice expressing the v-erbB oncogene in a heterozygous ink4a/arf background develop high-grade tumors with a predictable incidence. These tumors recapitulate many of the features of human high-grade tumors. For specific aim 1, animals will receive bone marrow transplants with fluorescently labeled cells so that bone- marrow derived cells can be identified precisely. The effect of cytokine activity upon glioma growth will be measured in specific aim 2 by crossing v-erbB expressing mice with mice that lack CCR2, the cellular receptor for MCP-1. Macrophage and microglia will be measured using immunohistochemistry and flow cytometry. The final specific aim will use intracranial implantation of transformed astrocytes to study the effect of either tumor- or host-derived MCP-1 on tumor growth. If the expected results are achieved, we would next evaluate inhibitors of the MCP-1/CCR2 signaling pathway as potential anti-tumor agents. Public Health Relevance: Inflammation accompanying malignant brain tumors results in complications for patients, and may promote the growth of tumors. Identifying the role of inflammation in brain tumors would provide a rationale to develop drugs to target this process. Another possible benefit of such drugs is that normal tissue injury associated with treatments such as radiation may also be reduced.

这个项目的目标是为申请者纳林·古普塔提供必要的专业知识，以开发 在加州大学旧金山分校的独立研究生涯 经验和训练。这将通过一个由Dr。 以色列F.查罗，以及在免疫学和转基因小鼠模型的使用方面的额外培训。古普塔博士是一位 对神经肿瘤学有临床和研究兴趣的儿科神经外科医生。他的项目是“巨噬细胞和 小胶质细胞在胶质瘤相关炎症中的激活1解决了脑瘤研究不足的一个方面 生物学：炎症细胞和肿瘤细胞之间的相互作用。这个项目的假设是 巨噬细胞和小胶质细胞通过过度表达一种特定的趋化因子而被招募到高级别胶质瘤中。 单核细胞化学吸引蛋白-1(MCP-1)，这一过程促进了肿瘤的生长。具体的 检验这一假设的目的是：a)确定肿瘤相关巨噬细胞的来源，b)测量 CCR2细胞因子受体缺失对小鼠少突胶质细胞瘤生长的影响 以及c)确定肿瘤和宿主来源的MCP-1对胶质瘤生长的贡献。重要的是 MCP-1在高级别胶质瘤中普遍存在，它与浸润性巨噬细胞的相关性，以及 数据支持这种细胞因子在血管生成和肿瘤细胞迁移中的作用。巨噬细胞的作用 而小胶质细胞对胶质瘤生长的影响将在转基因小鼠中使用遗传学方法直接进行检测。老鼠 在Ink4a/arf杂合子背景中表达v-erbB癌基因可发展为高级别肿瘤 可预见的事件。这些肿瘤概括了人类高级别肿瘤的许多特征。为 具体目标1，动物将接受带有荧光标记细胞的骨髓移植，以便骨- 骨髓来源的细胞可以被准确地鉴定。细胞因子活性对胶质瘤生长的影响将是 通过将表达v-erbB的小鼠与缺乏CCR2的小鼠杂交，在特定的目标2中进行测量 MCP-1受体。巨噬细胞和小胶质细胞将通过免疫组织化学和Flow进行检测。 细胞学。最终的具体目标是使用转化的星形胶质细胞在脑内植入来研究 肿瘤或宿主来源的单核细胞趋化蛋白-1对肿瘤生长的影响。如果达到预期的结果，我们将 接下来将评估MCP-1/CCR2信号通路的抑制剂作为潜在的抗肿瘤药物。 公共卫生相关性：炎症伴发恶性脑肿瘤导致并发症 患者，并可能促进肿瘤的生长。确定炎症在脑瘤中的作用将是 为开发针对这一过程的药物提供理论基础。这种药物的另一个可能的好处是 与放射等治疗相关的正常组织损伤也可能减少。